Rob N De Jong

USPTO Granted Patents = 17 (Patent Applications = 29)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 21)

Average Co-Inventor Count = 7.5

ph-index = 5

Forward Citations = 66(Granted Patents)

Location History:

Driebergen-Rijsenburg, NL (2020)
Utrecht, NL (2015 - 2024)

Company Filing History:

Years Active: 2015-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338289 - Antibody variant combinations and uses thereof (2025-06-24),

2. 12331123 - Agent, uses and methods for treatment (2025-06-17),

3. 12247065 - Method for producing a controlled mixture of two or more different antibodies (2025-03-11),

4. 12173076 - Polypeptide variants and uses thereof (2024-12-24),

5. 12049512 - Antibody variants and uses thereof (2024-07-30),

6. 11548950 - Agent, uses and methods for treatment (2023-01-10),

7. 11180572 - Dimeric protein with triple mutations (2021-11-23),

8. 10889650 - Agent, uses and methods for treatment (2021-01-12),

9. 10765743 - Antibodies binding AXL (2020-09-08),

10. 10759867 - Antibody variants and uses thereof (2020-09-01),

11. 10512688 - Antibodies binding AXL (2019-12-24),

12. 10500276 - Antibodies binding AXL (2019-12-10),

13. 10479835 - Agent, uses and methods for treatment (2019-11-19),

14. 10428147 - Anti-sortilin antibodies, uses and methods for treatment (2019-10-01),

15. 10201607 - Antibodies binding AXL (2019-02-12),

Title: Rob N De Jong: A Visionary Inventor Shaping the Future

Introduction: Rob N De Jong, a renowned inventor based in Utrecht, NL, is a trailblazer in the field of innovation with a total of 9 patents to his name. His groundbreaking work has revolutionized various industries and continues to inspire new generations of inventors worldwide.

Latest Patents: Rob N De Jong's latest patents showcase his ingenuity and commitment to advancing scientific knowledge. One of his recent inventions includes a dimeric protein with triple mutations, capable of forming a hexameric structure in solution. Additionally, he has patented antibodies binding AXL, opening new avenues for cancer treatment.

Career Highlights: Throughout his career, Rob N De Jong has made significant contributions to the field of biotechnology. He has worked with prestigious companies such as Genmab A+s and Genmab B.V., where his expertise and innovative spirit have driven numerous successful projects.

Collaborations: Collaboration plays a crucial role in Rob N De Jong's success. He has partnered with notable individuals in the industry, including Paul Parren and Edward Norbert Van Den Brink. Together, they have achieved remarkable milestones and pushed the boundaries of scientific discovery.

Conclusion: In conclusion, Rob N De Jong emerges as a visionary inventor whose dedication to innovation has had a profound impact on the world. His pioneering work not only transforms industries but also serves as a beacon of inspiration for aspiring inventors and innovators globally.

This text is generated by artificial intelligence and may not be accurate.